Announcements Trials

Browse Landscape

Phase

Status

Recruiting 2 Active not recruiting 2 Unknown 1 Terminated 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 11 Breast Neoplasms 10 Ovarian Neoplasms 9 Triple Negative Breast Neoplasms 8 Endometrial Neoplasms 8 Uterine Cervical Neoplasms 5 Esophageal Neoplasms 5 Stomach Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Fallopian Tube Neoplasms 4 Pancreatic Neoplasms 3 Neoplasms 3 Small Cell Lung Carcinoma 2 Recurrence 2 NSCLC 2 Mouth Neoplasms 2 Laryngeal Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Carcinoma, Ovarian Epithelial 2 Unresectable Locally Advanced or Metastatic Solid Tumors 1 Thyroid Neoplasms 1 Stage III and IV Ovarian Cancer 1 Squamous Non-small Cell Lung Cancer 1 Solid Tumor Cancer 1 Sarcoma, Kaposi 1 Respiratory Tract Neoplasms 1 Platinum-sensitive Relapsed Ovarian Cancer 1 Platinum-Resistant Primary Peritoneal Carcinoma 1 Pancreatic Intraductal Neoplasms 1 PDAC - Pancreatic Ductal Adenocarcinoma 1

Interventions

pyrotinib 5 Trastuzumab 4 pertuzumab 2 neratinib 1 exemestane 1 dalpiciclib 1 Paclitaxel 1 Leuprolide 1 Goserelin 1 Fulvestrant 1 Docetaxel 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × HER2-positive Breast Cancer × Paclitaxel × Clear all

NCT05388500 2022-05-27

PHARE-C

Institut de cancérologie Strasbourg Europe

Phase 3 Not yet recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡